Hepatitis C Continuum of Care Among Four Screening Populations in Durham County, North Carolina by Kovasala, Michael
 
 
 
 
 
 
 
Hepatitis C Continuum of Care  
Among Four Screening Populations in Durham County, North Carolina 
 
 
 
 
By 
Michael Kovasala 
 
 
 
 
 
 
 
 
 
 
 
 
Senior Honors Thesis 
Health Policy and Management 
The University of North Carolina at Chapel Hill 
 
 
May 2, 2019 
 
 
Approved: April 10, 2019    
 
 
____________________________________ 
Dr. Karl Umble, Thesis Advisor   
 
 
Dr. Asher Schranz, Reader     
 
 
Dr. Arlene Seña, Reader    
Introduction 
Hepatitis C (HCV) is the most common blood-borne viral infection in the United States.1 
In 2010, the CDC estimates there were 3.5 million people in the US living with chronic HCV, and 
new cases of acute HCV have tripled from 2010 to 2015.2  
The burden of HCV is high among vulnerable populations, such as racial minorities, people 
who inject drugs (PWID), and incarcerated persons.3,4 Among persons born between 1945 and 
1965 (the “birth cohort), which accounts for 74% of all chronic HCV cases, non-Hispanic blacks, 
and income below the poverty line have been shown to be significant predictors of chronic HCV 
infection.5 In a study of PWID in Baltimore, non-Hispanic black individuals were found to be at 
higher risk for HCV infection.6 HCV infection is also extremely prevalent in incarcerated 
populations. One study estimated that between 29% and 43% of those infected with HCV during 
that year passed through a correctional facility.7 Another study examining male inmates in Rhode 
Island prisons estimated a prevalence of 23.1% among those incarcerated 12 months or more.8 
Yet, many individuals with HCV are either not diagnosed or unaware of their infection not aware 
of being infected.9 Persons who are younger, uninsured, never been tested for HIV, or who use 
drugs but who are not engaged in substance use disorder treatment are less likely to be 
diagnosed.9,10 
The continuum of care is a model that has been proposed to conceptualize progress through 
the milestones of HCV care, from screening and diagnosis to sustained viral response at 12 weeks 
(SVR-12, or functional cure).11 Therapies for HCV have become increasingly safe and effective 
with the introduction of direct-acting antivirals (DAAs),12,13 which have been shown to help 
patients achieve SVR in over 90% of cases with treatment courses as short as 8 weeks.14 However, 
progression through the continuum remains poor. Although screening for HCV, as recommended 
by the CDC and the US Preventive Services Task Force,15,16 is becoming more common, there 
remains a large gap between a positive screening result and beginning treatment.17 One study of 
persons living with HCV in Long Island, New York noted that of 155 HCV-positive individuals, 
only 110 (71%) had a follow-up HCV RNA test, and only 54 (35%) were successfully linked to 
care.11 In one nationally representative systematic review, it was estimated that only 9% of persons 
with chronic HCV in the US had progressed through the continuum of care to achieve SVR.18 
The continuum may be worse for vulnerable populations. One study found that of 187 
Chronic HCV-infected patients meeting inclusion criteria, only 107 (57%) completed treatment.19 
In this study population, across univariate and multivariate analyses, patients with Medicaid 
insurance were less likely to complete an evaluation and less likely to be approved for treatment, 
pointing to a need for improved targeted interventions to close these and other gaps. A nationally 
representative 2016 study by Bourgi et al. confirmed that Medicaid beneficiaries who screened 
positive for HCV had significantly lower odds of treatment.20 
Problem Statement 
The continuum model presents an opportunity to examine how patients in diverse settings 
progress through the HCV treatment milestones, and can help identify opportunities for 
intervention to ensure patients achieve SVR. 
Research Questions 
This study examines outcomes for populations screened for HCV in four different care settings: 
a county jail, a local Federally Qualified Health Center (FQHC), the county health department, 
and its various non-jail outreach programs. The study was designed to address the following 
questions: 
• What are the differences in demographics and risk factors between screening settings? 
• Where do drop-offs occur in the continuums, and how do these differ between screening 
settings? 
• What are factors associated with patients being prescribed treatment? 
 
Methods 
Study Design 
We conducted a retrospective cohort study of patients enrolled in a pilot program 
implemented by the Durham County Health Department (DCHD) to enhance linkage to care for 
Hepatitis C virus infection (HCV). The pilot program utilized bridge counselor services to screen 
at-risk patients for HCV, provide pre- and post-test counseling, and link HCV-infected patients to 
care through partnerships with treating providers in and around Durham County. Data for patients 
in that process was routinely abstracted for program monitoring purposes. While the DCHD 
linkage-to-care program only extends to linking patients to their first appointment, patients were 
monitored through their HCV care through the end of treatment via collaboration and data-sharing 
with partner sites. 
Settings and Populations 
The program conducted HCV testing in four sites: the sexual health clinic of the DCHD, 
the Durham County jail, the Lincoln Community Health Center (an FQHC in Durham County), 
and a community outreach screening program which operated at several sites, including a 
residential substance abuse recovery program. These care settings serve populations who may be 
distinct in demographics, HCV risk factors and clinical comorbidities. Therefore, we chose to 
investigate differences in the data between these care settings. 
Program Testing and Linkage to Care Process 
Program HCV Testing Process: HCV screening was offered based on AASLD-IDSA 
HCV guidelines,11 evaluating such risk factors as: history of injection drug use, HIV infection, 
birth between 1945 – 1965 (“birth cohort”), history of incarceration, long-term sexual exposure to 
an HCV-infected person, history of multiple sexual partners, or male-to-male sexual contact. The 
Durham County jail offered opt-out HCV testing to all inmates; two health educators each visited 
the jail at least two times per week, and conducted testing in different pods. Other locations 
selectively screened based on aforementioned risk-factors.  
Risk factors were assessed at the DCHD and through their non-jail outreach programs using 
a standardized self-report form. At Lincoln, risk factors were assessed using a similar form, also 
based on accepted evidence-based HCV guidelines. The Durham County Jail collected risk factor 
data but offered HCV testing to all inmates on an opt-out basis.  
Testing was typically conducted on-site via existing phlebotomy services, or in a mobile 
testing unit. HCV antibody testing was conducted in all settings with automatic reflex to HCV 
RNA testing upon positive results. 
Linkage-to-Care Intervention: The program’s linkage-to-care intervention aimed to 
ensure persons had a first visit with an HCV-treating provider. There was approximately 6-8 weeks 
from the initial screening to the first appointment. A bridge counselor assisted with post-test 
counseling and met with patients (in-person at the DCHD, at home visits, or via telephone) to assist 
in scheduling appointments, address transportation barriers and send appointment reminders. 
Bridge counseling services concluded once a patient attended their first appointment with a treating 
provider. 
Hepatitis C Continuum of Care 
We constructed multiple continuums of care to analyze patient progression through 
milestones reflecting progression through HCV screening and treatment. Steps in the continuum 
include: (1) Diagnosis of HCV (2) Of those diagnosed with HCV, receipt of test results and post-
test counseling, (3) of those notified and counseled, referral to HCV care, (4) of those referred to 
care, attendance at first appointment with a treating provider (“linkage”), (5) of those linked to 
care, prescription of antiviral to treat HCV, (6) of those prescribed HCV treatment, receipt and 
start of antivirals, (7) of those starting antivirals, completion of medication course and, (8) of those 
completing medication, confirmation of undetectable HCV RNA level at least twelve weeks later 
(sustained viral response, SVR-12).21 From initial screening to achieving SVR-12, the entire 
process lasts approximately nine to twelve months. Therefore, we selected patients who began the 
process prior to October 31, 2017 (twelve months before the most recent data), to ensure they had 
sufficient time to move through the full continuum of care. 
Data Analysis 
Continuum Analysis: An overall continuum of all patients was constructed. We assessed 
the total number of patients meeting each milestone, as well as the proportion of HCV-infected 
patients. The continuum was also stratified by the setting in which a patient was screened for HCV. 
We then compared each milestone between settings to determine if specific settings of diagnosis 
were associated with drop-off from the continuum. We employed an ANOVA test to compare 
differences in patient drop-off between settings. 
Logistic Regression: We then constructed a multivariable logistic regression model, 
evaluating the effect of screening location on successful receipt of prescription. We adjusted for 
age, sex, race/ethnicity, insurance status and patient HCV risk factor(s). Statistical significance 
was defined as a p-value of <0.05. For the 37 patients who were screened in the jail and referred 
to a prison clinic we were unable to obtain data on whether or not they were prescribed treatment, 
and thus these patients were considered lost to follow-up. Therefore, we were forced to censor all 
patients linked to a prison clinic from our analysis. 
Results 
Demographics 
Overall, 573 persons received a positive HCV antibody screening test with a subsequent 
confirmatory positive HCV RNA. The largest proportion of persons (46%) were diagnosed at the 
FQHC. Patients had a mean age of 47 (SD 13), were primarily black (65%) male (73%) residents 
of the city of Durham (84%) who were either uninsured (54%) or insured by Medicaid (21%) 
(Table 1). Persons diagnosed in the jail were younger (mean age 38, SD 12) and more commonly 
Non-Hispanic White (60%), compared with other sites. Race/ethnicity data was missing on 71% 
of FQHC patients, as this data is not routinely collected at the site.  
The majority of patients (61%) were linked to a primary care provider (PCP) treating HCV, 
while others were linked to either a specialty clinic (39%) or a prison clinic (10%). Linkage to a 
PCP was most common for individuals screened in the county health department (64%) and at the 
FQHC (73%), while the most common referral for those screened through non-jail outreach was a 
specialty clinic (54%). The proportion of persons linked to care was lowest among those diagnosed 
at the jail (61%). 
Information on HCV risk factors were available for a majority of patients; 73% reported a 
history of injection drug use and 45% had used non-injected drugs. Among all patients diagnosed, 
3% were coinfected with HIV, 22% reported tattoos or piercings, and 40% had a history of 
incarceration. Other risk factors among all patients diagnosed include male-to-male sexual contact 
(MSM) (8%), sexually transmitted infection (6%), engaging in sex with a person who inject drugs 
(13%), sex with a person with HCV (11%), sex with multiple partners (11%), and exchanging sex 
for drugs or money (6%). Nearly half of all patients (48%) were members of the birth cohort, born 
between 1945 and 1965. Prevalence of birth cohort members was lowest in the jail (19%) and 
highest in the FQHC (66%). 
Continua of Care 
In the overall continuum, 89% (449 patients) of those with chronic HCV were counseled 
on their diagnosis (Figure 1). 65% of all diagnosed (329 patients) were linked to care with an HCV-
treating provider, representing a drop-off of 24% between counseling and linkage to care (Figure 
3). Of eligible patients, 41% (192 patients) were prescribed treatment, representing a patient drop-
off of 24% between linkage to care and prescription of treatment. Subsequently, 38% of patients 
(176) began treatment, and 34% (160) completed therapy. Of all eligible patients with chronic 
HCV, 24% (111) successfully achieved SVR-12. 
For those diagnosed at the FQHC, the most substantial drop-off occurred from the 
proportion of eligible patients linked to care (83%) to those who were prescribed medication (59%) 
(Figure 2). For the county health department, the most prominent gap was between the same two 
milestones, decreasing from 74% of patients linked to care to 49% who were prescribed 
medication.  
For non-jail outreach, there was a 35% drop-off from counseling to linkage to care (86% 
counseled and 51% linked to care). For those diagnosed at the jail, under half of those who were 
counseled on their diagnoses (85% of all persons diagnosed) were linked to care (42%). Among 
the 122 persons diagnosed in jail and not linked at a prison clinic, where subsequent treatment 
information was not available, 10 patients (8%) were prescribed medication.  
Logistic Regression 
In univariate analyses, screening site was significantly associated with patient receipt of 
HCV prescription; patients diagnosed at the county jail (OR: 0.07, 95%CI: 0.04, 0.15) and those 
diagnosed through non-jail outreach (OR: 0.42, 95%CI: 0.24, 0.74) had significantly lower odds 
of being prescribed HCV treatment compared to the FQHC, while there was no significant 
difference between the county health department and the FQHC. Age was significantly associated 
with patient receipt of HCV prescription; a one-year increase in age was associated with 5% greater 
odds of being prescribed HCV treatment. In the unadjusted model, race was also found to be a 
determinant of treatment, with non-Hispanic blacks (OR: 10.87, 95%CI: 4.55, 25.99), individuals 
of Hispanic ethnicity or other nonwhite race (OR: 6.06, 95%CI: 1.58, 23.23), and individuals of 
unknown race (OR: 11.09, 95%CI: 4.64, 26.51) more likely to be prescribed HCV treatment 
compared to non-Hispanic whites. Other significant mediating factors of receiving a prescription 
were residence within the city of Durham (OR: 2.21, 95%CI: 1.27, 3.84), being a member of the 
birth cohort (OR: 2.81, 95%CI: 1.96, 4.04), and being linked to a specialty clinic as opposed to a 
primary care provider (OR: 3.63, 95%CI: 2.07, 6.38). 
After adjusting for sociodemographic and risk factors, variables significantly associated 
with prescription of HCV treatment were diagnosis through non-jail outreach (OR: 0.33, 95%CI: 
0.12, 0.89) as well as linkage to a specialty clinic (OR: 3.82, 95%CI: 1.95, 7.46). The Odds Ratio 
for the patients diagnosed in jail became nonsignificant in our adjusted model. 
Discussion 
In this study spanning a large urban county, we observed that 24% of persons diagnosed 
with HCV in four safety-net settings achieve SVR-12. The site of screening significantly predicted 
being prescribed medications for HCV treatment. After controlling for demographics and risk 
factors, persons linked to care at a specialty clinic had greater odds of being prescribed HCV 
treatment. Notably, insurance status did not impact the odds of receiving HCV treatment.  
There is extensive literature examining HCV screening in different of settings. However, 
there is little data on how these screening sites compare to one another within the same community, 
resulting in inadequate knowledge of where interventions should be targeted in a given region.  
We found that less than two-thirds of persons diagnosed with HCV (65%) were linked to 
care with an HCV-treating provider. Our experience in Durham County is consistent with reports 
from other sites and is not limited to the Southeastern US. In a comparable community outreach 
screening program conducted in New Haven, CT, 63% of individuals receiving a positive HCV 
screen were successfully linked to care, compared to 51% of individuals in our study.22 A 
community outreach screening program in Philadelphia, which also included on-site phlebotomy 
testing and immediate automatic reflex to RNA testing, linked 64% of their patients to care.23 
Another study conducted in Philadelphia examined HCV screening conducted in five FQHCs, and 
found similar rates of success in linkage to care; across all five FQHCs, 78% of individuals with a 
current HCV infection were linked to care, which is generally similar to the 83% linkage rate 
observed in the FQHC in our study.24 However, individuals in that report were all linked to HCV-
specialty clinics, while individuals screened at Lincoln were variably linked to either a Primary 
Care Provider (PCP) or a Specialty Clinic. Our study found that receipt of a prescription for HCV 
treatment significantly predicted by whether patients were linked to care at a specialty clinic 
compared to a primary care clinic or prison clinic. Understanding the barriers to prescription of 
HCV treatment in primary care settings may help spur improvements along the latter steps of the 
cascade. 
The Durham County Health Department is unique in providing surveillance for chronic 
HCV, offering on-site HCV antibody testing with reflex to RNA testing, and utilizing an in-house 
bridge counselor to facilitate linkage to care.21,22,25,26 Persons diagnosed through the county health 
department were only slightly less frequently linked to care than those diagnosed at the FQHC site 
(74% of patients to linked, compared with 83%). This success carried over to ensuring patients 
were actually prescribed treatment: 49%, compared with the FQHC’s 59%. Bridge counseling 
services can be an important tool in helping individuals navigate the milestones of HCV care, 
especially in the setting of otherwise limited access to care, noninsurance or low health literacy. 
Our study focused on the proportion of persons living with HCV who are prescribed 
treatment. Many evaluations of linkage-to-care programs cease to follow patients at the point of 
linkage to care.27 For example, in one study of a community-based linkage to care model, of 512 
patients with a current HCV infection, 435 (85%) were linked to care. The study concluded that 
its community-based model successfully had linked a large proportion of persons living with HCV 
to care; however, the study noted that only 14 of these patients actually initiated treatment, and of 
those, only 6 achieved functional cure. Given that a small proportion (2.7%) actually received care, 
and an even smaller proportion (1.2%) actually achieved functional cure, one may argue whether 
linkage to care is an adequate surrogate outcome for meaningful HCV care8,28,29 Our study also 
found a substantial drop-off the cascade after linkage to care. Providing resources to safety-net 
settings to enhance patient navigation services in the latter steps of the cascade would likely 
improve community-level SVR-12 rates and thereby improve population-level clinical outcomes 
and decrease ongoing transmission. 
Jails are a setting with significant opportunity for improvement in HCV screening and 
treatment. The prevalence of HCV in jails is higher than in the population at large, though it is 
lower than the prevalence within the prison population.30 Despite high prevalence, jails typically 
struggle with linking patients with post-release HCV care.31 This is compounded by societal 
factors that impede access to housing and employment for individuals post-release.32 Programs 
targeted towards post-release individuals show promise in linking these individuals to care, but 
large gaps remain; in a linkage-to-care intervention implemented in a North Carolina jail, just 18 
of 66 individuals with a current HCV infection were referred to medical care, and of these, only 
10 attended their first medical appointment.33 Our intervention saw a higher proportion of 
individuals linked to care (42% vs. 27%), but only 10% were confirmed to have been prescribed 
treatment, suggesting that substantial improvements in care are needed further down the cascade.  
Importantly, our study found that insurance status was not a significant predictor of being 
prescribed HCV treatment. This contradicts a nationally representative study of nearly 30,000 
persons living with chronic HCV conducted by Wong et al. in 2018, which found that Medicaid 
beneficiaries and uninsured individuals had significantly lower odds of receiving treatment 
compared to individuals with private insurance (ORs 0.21 and 0.19, respectively).34 We 
hypothesize that the lack of a significant difference in our study may be attributable to the success 
of the bridge counselor intervention in linking Medicaid beneficiaries and uninsured individuals 
to care. Additionally, we suspect that treatment over this study period was facilitated by the 
loosening of restrictions for treatment paid by Medicaid and expansion of Prescription Drug 
Assistance Programs by pharmaceutical companies for uninsured patients. 
Application to Future Public Health Interventions 
In our study, 44% of individuals screened in the Durham County jail dropped-off the 
cascade between the bridge counseling appointment and linkage to care. This finding suggests two 
possible opportunities for intervention. First, initiation of HCV therapy in the jail at the time of 
diagnosis may help streamline care and ensure patients take this critical step in HCV treatment. 
Second, persons released from jail may benefit from enhanced bridge counseling and navigation 
services to ensure they are linked to medical providers in the community. Qualitative analyses 
examining the experiences of persons accessing HCV care following jail release will be an 
important first step in identifying challenges and designing interventions. 
Understanding and overcoming barriers to antiviral prescription in primary care settings is 
also a critical step in improving community-wide outcomes. In our regression model, we found 
that linkage to a specialty clinic was the strongest predictor of being prescribed treatment 
(Adjusted Odds Ratio: 3.82, 95% CI: 1.95, 7.46). Given the burden of chronic HCV nationwide, 
streamlining referral pathways to specialty providers is unlikely to represent a sustainable and 
generalizable solution. Rather, educational initiatives in HCV care should target primary care 
clinicians, while primary care practices should develop pathways for integrating HCV treatment 
into routine practice. One initiative implemented by the University of New Mexico, the Extension 
for Community Healthcare Outcomes (ECHO) model, aimed to train PCPs in HCV management. 
A program evaluation found that prior to this training, 93% of enrolled clinicians had no prior 
experience in the care and treatment of HCV.35 Similarly, a study of primary care settings in 
Baltimore found that only 10% of PCPs enrolled in the study had treated 1 or more HCV patient 
in the past year. Nonetheless, shifting HCV treatment to a primary care setting appears feasible 
and even ideal, given that HCV therapy can be provided over the course of only several visits, 
requires minimal lab monitoring and typically utilizes medications with few potential side effects. 
North Carolina, in partnership with two academic medical centers, has developed the Carolina 
Hepatitis Academic Mentorship Program (CHAMP) which conducts trainings and mentorship to 
equip the primary care workforce statewide with the tools and experience to treat HCV.36 
Enhancing the reach of these programs, combined with expanded patient navigation services, may 
be the most promising initial steps to addressing HCV in underserved populations. 
Strengths and Limitations 
Strengths of this study include the comparison of progression through the HCV continuum 
of care across four different screening settings which serve demographically unique, largely 
uninsured patient populations across a single large and diverse county. While there is a significant 
body of literature examining the HCV continuum of care in a variety of treatment settings, there 
is a dearth of studies comparing HCV continuums based on the setting in which patients are 
initially diagnosed, prior to linkage to care. 
Although our findings on one county may limit generalizability, the focus on one urban 
county in the Southeastern US highlights the state of HCV care in one of the most HCV-prevalent 
regions in the US.35 North Carolina is also in the minority of states who have not expanded 
Medicaid under the Affordable Care Act, and as such there may be a greater number of uninsured 
individuals in our study than similar studies in Medicaid expansion states, which may limit 
comparisons of our data. Additionally, our study collected data on the last four steps of the 
continuum from chart review, which lacks information on patient comorbidities, preferences and 
medical decision-making. Data on HCV treatment of persons in prison was missing in our study, 
limiting interpretation of the latter steps of the cascade for persons diagnosed in jail. Finally, the 
FQHC does not routinely collect data on race (71% missing), and for this reason a relatively large 
proportion (38%) of our data was missing this information, limiting our assessment of race as a 
mediating factor in receiving HCV treatment. Additionally, as mentioned in the Methods section, 
the 37 patients who were screened in the jail and referred to a prison clinic were considered lost to 
follow-up, and were censored from further analysis. 
Conclusions 
In this large study of safety-net systems for HCV diagnosis and care, we observed that 
progression through the HCV continuum of care is associated with the location of diagnosis. 
Individuals screened at the FQHC were most likely to be prescribed treatment and eventually 
achieve functional cure, while individuals screened in community outreach settings were the least 
likely. Prescription of HCV treatment was significantly more likely for individuals who were 
linked to specialty clinics than those linked to primary care, indicating an opportunity for 
improvement of HCV care delivery in primary care settings. Additional research is needed to better 
understand the specific barriers that limit progression through the steps of the cascade and to design 
novel interventions to help improve HCV outcomes for the whole community.  
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Appendix 
 
Table 1. Demographic and risk factor data, stratified by screening setting 
Item Notes Overall DCHD* FQHC** Jail Outreach 
N 
 
573 77 261 167 72 
Age Mean (SD) 47.45 
(13.31) 
45.73 
(13.64) 
53.33 
(10.80) 
38.13 
(11.65) 
48.29 
(12.78) 
Demographic Factors n (%) 
     
Gender 
      
 
Male Sex 421 (73%) 51 (66%) 189 (72%) 138 (83%) 43 (63%)  
Female Sex 151 (26%) 26 (34%) 72 (26%) 28 (17%) 25 (37%)  
Transgender 1 (<1%) 0 (0%) 0 (0%) 1 (<1%) 0 (0%) 
Durham City Res. 
      
 
Durham Res. 464 (84%) 
    
 
Non-Durham 86 (16%) 
    
 
Freq. Missing 23 
    
Race/ Ethnicity 
      
 
Non-Hispanic 
White 
108 (30%) 1 (2%) 0 (0%) 101 (60%) 6 (10%) 
 
Non-Hispanic 
Black 
229 (65%) 49 (96%) 69 (91%) 57 (34%) 54 (89%) 
 
Hispanic / Latino 11 (3%) 0 (0%) 4 (5%) 7 (4%) 0 (0%)  
Other/Unknown 7 (2%) 1 (2%) 3 (4%) 2 (1%) 1 (2%)  
Freq Missing 218 26 185 0 7 
Insurance 
      
 
Private 27 (5%) 5 (6%) 7 (3%) 12 (7%) 3 (4%)  
Medicare 38 (7%) 4 (5%) 16 (6%) 13 (8%) 5 (7%)  
Medicaid 120 (21%) 15 (19%) 57 (22%) 39 (23%) 9 (13%)  
Other/Unknown 79 (14%) 13 (17%) 36 (14%) 18 (11%) 12 (18%)  
None 309 (54%) 40 (52%) 145 (56%) 85 (51%) 39 (57%) 
Linkage to Care Site 
      
 
Primary Care 221 (61%) 35 (64%) 151 (73%) 19 (29%) 16 (46%)  
Specialty Clinic 104 (39%) 20 (36%) 56 (27%) 9 (14%) 19 (54%)  
Prison Clinic 37 (10%) 0 (0%) 0 (0%) 37 (57%) 0 (0%)  
Not Linked 211 22 54 102 33 
HCV Risk Factors n (%) 
     
Injection drug use 
      
 
Yes 374 (73%) 43 (64%) 176 (76%) 104 (68%) 51 (81%)  
No 139 (27%) 24(36%) 55 (24%) 48 (32%) 12 (19%)  
Freq Missing 60 10 30 15 5 
Non-injection drug use 
      
 
Yes 232 (45%) 31 (46%) 109 (47%) 67 (44%) 25 (40%)  
No 282 (55%) 36 (54%) 123 (53%) 85 (56%) 38 (60%)  
Freq Missing 59 10 29 15 5 
HIV+ 
      
 
Yes 13 (3%) 3 (4%) 7 (3%) 2 (1%) 1 (2%)  
No 500 (97%) 65 (96%) 226 (97%) 147 (99%) 62 (98%)  
Freq Missing 60 9 28 18 5 
Tattoos or piercings 
      
 
Yes 112 (22%) 18 (26%) 59 (25%) 24 (16%) 11 (18%)  
No 400 (78%) 50 (74%) 173 (75%) 127 (84%) 50 (82%)  
Freq Missing 61 9 29 16 7 
H/o incarceration 
      
 
Yes 213 (40%) 29 (41%) 117 (48%) 44 (28%) 23 (36%)  
No 318 (60%) 41 (59%) 125 (52%) 111 (72%) 41 (64%) 
 
Freq Missing 42 7 19 12 4 
MSM 
      
 
Yes 40 (8%) 10 (15%) 19 (8%) 10 (7%) 1 (2%)  
No 474 (92%) 58 (85%) 215 (92%) 139 (93%) 62 (98%)  
Freq Missing 59 9 27 18 5 
STI+ 
      
 
Yes 30 (6%) 3 (4%) 14 (6%) 9 (6%) 4 (6%)  
No 482 (94%) 64 (96%) 218 (94%) 141 (94%) 59 (94%)  
Freq Missing 61 10 29 17 5 
Sex with PWID 
      
 
Yes 68 (13%) 6 (9%) 41 (18%) 13 (9%) 8 (13%)  
No 454 (89%) 60 (91%) 191 (82%) 137 (91%) 55 (87%)  
Freq Missing 62 11 29 17 5 
Sex with HCV+ person 
      
 
Yes 58 (11%) 15 (22%) 20 (9%) 18 (12%) 5 (8%)  
No 454 (89%) 52 (78%) 212 (91%) 132 (88%) 58 (92%)  
Freq Missing 61 10 29 17 5 
Sex w multiple partners 
      
 
Yes 55 (11%) 8 (12%) 31 (13%) 10 (7%) 6 (10%)  
No 449 (89%) 56 (88%) 199 (87%) 138 (93%) 56 (90%)  
Freq Missing 69 13 31 19 6 
Sex for drugs/money 
      
 
Yes 30 (6%) 5 (7%) 15 (6%) 7 (5%) 3 (5%)  
No 482 (94%) 62 (93%) 217 (94%) 143 (95%) 60 (95%)  
Freq Missing 61 10 29 17 5 
BT before 1992 
      
 
Yes 26 (5%) 7 (11%) 5 (2%) 10 (7%) 4 (6%)  
No 479 (95%) 57 (89%) 226 (98%) 138 (93%) 58 (94%)  
Freq Missing 68 13 30 19 6 
Birth Cohort member 
      
 
Yes 276 (48%) 33 (43%) 173 (66%) 32 (19%) 38 (56%)  
No 297 (52%) 44 (57%) 88 (34%) 135 (81%) 30 (44%)  
Freq Missing 0 0 0 0 0 
*Durham County Health Department. **Federally Qualified Health Center (Lincoln). 
 
Table 2. Univariate and Adjusted Odds Ratios of Receiving HCV Prescription 
Variable Category Univariate OR (95%CI) Adjusted OR (95% CI) 
Screening Site 
 
   
Lincoln FQHC ref 
 
 
DCHD 0.77 (0.46, 1.28) 0.61 (0.27, 1.37)  
DC Jail 0.07 (0.04, 0.15) 0.29 (0.08, 1.07)  
Non-Jail Outreach 0.42 (0.24, 0.74) 0.33 (0.12, 0.89) 
Age age 1.05 (1.04, 1.07) 1.00 (0.96, 1.04) 
Sex 
   
 
Female ref 
 
 
Male 0.77 (0.52, 1.13) 0.70 (0.38, 1.28) 
Race/Ethnicity 
   
 
Non-Hispanic White ref 
 
 
Non-Hispanic Black 10.87 (4.55, 25.99) 2.03 (0.43, 9.60)  
Hispanic/Other 6.06 (1.58, 23.23) 1.74 (0.18, 16.65)  
Unknown 11.09 (4.64, 26.51) 1.06 (0.21, 5.37) 
Insurance Status 
   
 
Private Insurance ref 
 
 
Medicare 1.43 (0.47, 4.31) 0.73 (0.14, 3.85)  
Medicaid 1.53 (0.59, 3.95) 0.76 (0.18, 3.24) 
 
Other or Unknown 2.57 (0.97, 6.79) 1.61 (0.33, 7.73)  
Uninsured 1.87 (0.77, 4.55) 1.23 (0.31, 4.95) 
IDU 
   
 
No ref 
 
 
Yes 1.34 (0.88, 2.05) 1.03 (0.54, 1.94) 
HIV 
   
 
No ref 
 
 
Yes 0.71 (0.22, 2.34) 0.49 (0.10, 2.44) 
MSM 
   
 
No ref 
 
 
Yes 0.68 (0.33, 1.41) 0.65 (0.23, 1.80) 
Site of linkage to HCV Care 
   
 
Primary Care ref 
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Birth Cohort No ref 
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